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Understanding the basis of the unrestricted multilineage differentiation potential of pluripotent cells will be of
developmental and translational consequence. We propose that pluripotency transcription factors are
lineage specifiers that direct commitment to specific fetal lineages. Individual factors bestow the ability to
differentiate into particular cell types, and concomitant expression ofmultiple lineage specifiers within plurip-
otent cells enables differentiation into every fetal lineage. Moreover, we speculate that, rather than being an
intrinsically stable ‘‘ground state,’’ pluripotency is an inherently precarious condition in which rival lineage
specifiers continually compete to specify differentiation along mutually exclusive lineages.Pluripotent cells, such as mouse embryonic stem cells (ESCs)
and their embryological antecedents—the cells of the peri-
implantation epiblast—have the capacity to differentiate into
any cell type present within the fetus. Hence, pluripotent cells
exist at the summit of the proverbial mountain of developmental
potential (as illustrated by Graf and Enver, 2009). How such
a vast range of lineage choices is made available remains
cryptic, however. We herein articulate a speculative basis for
the unrestricted multilineage differentiation potential of pluripo-
tent cells, founded on a reinterpretation of existing findings.
Instead of imagining pluripotency as an intrinsically stable
‘‘ground state’’ (Jaenisch and Young, 2008; Silva and Smith,
2008; Wray et al., 2010; Young, 2011), we envisage that it is
inherently unstable and that pluripotency is defined by transcrip-
tional competition between the lineage-specifying actions of
pluripotency factors.
Pluripotency Factors Are Lineage Specifiers
The pluripotent state is supervised by a regime of transcription
factors that endow ESCs with their salient characteristics—as
Silva and Smith have summarized aptly, ‘‘transcription factors
rule pluripotency’’ (Silva and Smith, 2008). Loss of individual pluri-
potency transcription factors frequently prompts ESC differentia-
tion tospecific lineages (reviewedbyLessardandCrabtree,2010).
Based on such findings, the current model of pluripotency
proposes that individual pluripotency factors act to prohibit
ESC cell differentiation along specific lineages (Figure 1A) and
that, as a result, ESCs are ensconced by a shield of protective
transcription factors that collaboratively inhibit differentiation to
all lineages in order to preserve an undifferentiated state (Jae-
nisch and Young, 2008; Silva and Smith, 2008; Young, 2011).
This model accounts for how ESCs can remain undifferentiated
but provides little explanation for their multilineage differentiation
potential. Indeed, if pluripotency factors redundantly upregulate
one anothers’ expression while constitutively inhibiting differen-
tiation (Jaenisch and Young, 2008; Silva and Smith, 2008;
Young, 2011), it would in fact seem difficult for ESCs to ever
differentiate and commit to any subordinate lineage.One of the fundamental predictions of this prevailing hypoth-
esis is that overexpression of individual pluripotency factors
should prohibit ESC differentiation. However, it has been repeat-
edly found that overexpression of pluripotency factors in ESCs
often induces differentiation. For example, overexpression of
the classical pluripotency factor Oct4 specifies mesodermal
differentiation (Niwa et al., 2000); Sox2 overexpression prompts
neuroectodermal specification (Kopp et al., 2008); overexpres-
sion of Esrrb, Sall4, or Tbx3 elicits endodermal determination
(Ivanova et al., 2006; Lu et al., 2011; Zhang et al., 2006); and
overexpression of Dax1 directs trophectodermal respecification
(Sun et al., 2009). Moreover, Nanog overexpression in human
ESCs directs mesendodermal differentiation (Teo et al., 2011;
Yu et al., 2011), and Sip1 overexpression begets neuroectoder-
mal commitment (Chng et al., 2010). Recent high-throughput
studies have also identified additional pluripotency factors
that similarly provoke ESC differentiation when overexpressed
(Ivanova et al., 2006; Nishiyama et al., 2009).
These findings that pluripotency factor overexpression
frequently prompts ESC differentiation are difficult to reconcile
with previous assertions that pluripotency factors constitutively
suppress lineage commitment (Jaenisch and Young, 2008; Silva
and Smith, 2008; Young, 2011). To overcome such difficulties,
we would like to suggest a complementary hypothesis for the
consideration of the field.
We propose that many pluripotency factors function as
classical lineage specification factors (reviewed by Enver and
Greaves, 1998), directing ESC differentiation to a specific fetal
lineage while prohibiting commitment to mutually exclusive line-
ages. Thus, we envisage that pluripotency is not maintained by
a regime of inhibitory transcription factors that cooperatively
block differentiation to all lineages. Instead, we propose an
alternative scenario in which many individual pluripotency
factors are continually attempting to specify ESC differentiation
to their own lineage of interest (Figure 1A).
Furthermore, we venture that the ability of ESCs to differen-
tiate into specific lineages derives from their intrinsic lineage
specifiers, each of which provides ESCs with the ability toCell Stem Cell 8, April 8, 2011 ª2011 Elsevier Inc. 363
Figure 1. The Transcriptional Agency that Oversees Pluripotency
(A) A divided coalition of competing transcription factors oversees pluripotency. Pluripotency transcription factors exert lineage-specific blockades on
differentiation to particular lineages (hatched orange lines) while often concomitantly directing differentiation to an alternative lineage (blue arrows). Hence,
pluripotency factors function as classical lineage specifiers, and confer ESCs with the ability to differentiate to specific fetal lineages—thus providing a basis for
the multilineage differentiation potential of pluripotent cells. Coincident expression of diverse lineage specifiers within undifferentiated ESCs leads these factors
to cross-inhibit one another, resulting in no net commitment to any particular lineage. Nevertheless, slight perturbations in the expression of any transcription
factor would result in collapse of this fragile transcriptional equilibrium and consequential lineage commitment—hence, pluripotency is inherently transcriptionally
insecure. TF, transcription factors.
(B) Pluripotency factors direct the lineage specification of ESCs by upregulating lineage determinants. Pluripotency factors activate differentiation gene batteries
by potentiating expression of both master drivers and terminal differentiation effectors (Davidson, 2010). Here, the definitive endoderm differentiation gene
battery is shown, reconstructed from data taken from human ESCs, mouse ESCs, andmouse development. Nanog upregulates Eomes, one of themaster drivers
of the definitive endoderm differentiation gene battery, while Foxd3 concomitantly binds to albumin (Alb1) and keeps it free of DNA methylation and ready for
expression. As the epiblast segues to definitive endoderm, Foxa1 andGata4 replace Foxd3 in potentiatingAlb1 expression, and as hepatic differentiation occurs,
accessory transcription factors (e.g., Hnf1a) accumulate onAlb1, finally leading to its expression. Asterisks denote epigenetic potentiation of differentiation genes
by pluripotency factors in ESCs.
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example, Oct4 confers ESCs with the capability to differentiate
into mesoderm (Zeineddine et al., 2006), whereas Nanog
provides the ability to differentiate into definitive endoderm
(Teo et al., 2011). In our model, the expression of a myriad of
diverse lineage specifiers within ESCs provides them with all
the developmental regulators necessary to differentiate toward
any major fetal lineage.
Ourparadigmalsooffers anexplanation forwhy tissue-specific
differentiation factors such as Sox2 and Zic3 are expressed in364 Cell Stem Cell 8, April 8, 2011 ª2011 Elsevier Inc.and are important for ESCs, whichwould be difficult to rationalize
a priori. We propose that these lineage determinants reprise
some of their roles in fetal development within pluripotent
cells in order to enableESCs todifferentiate towards specific fetal
lineages.
Lineage Specification by Pluripotency Factors: Testing
the Model
As discussed above, previous investigations have found that that
many pluripotency factors have explicit lineage specifying
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reify our proposed model.
In particular, while exogenous pluripotency factor overexpres-
sion frequently elicits ESC differentiation to specific lineages, it is
important to ascertain whether these factors are endogenously
required for ESCs to differentiate into these cell types. One intu-
itive experiment is to knock down individual lineage-specifying
pluripotency factors within ESCs and then test whether these
cells can still differentiate into the relevant lineages.
This type of experiment has already been performed for some
factors. Knockdown of mesodermal determinant Oct4 immedi-
ately before differentiation renders ESCs largely incapable of
mesodermal differentiation (Zeineddine et al., 2006). Likewise,
knockdown of the primitive endoderm sponsor Tbx3 abrogates
the ability of mouse ESCs to differentiate into primitive endoderm
(Lu et al., 2011), and loss of the endodermal specifier Nanog in
human ESCs compromises their capacity for mesendodermal
differentiation (Teo et al., 2011). From such findings, we surmise
that Oct4, Nanog, and Tbx3 represent bona fide lineage speci-
fiers that confer ESCs with the ability to differentiate into specific
embryonic lineages.
It will also be illuminating to test whether pluripotency factors
operate as lineage specifiers in vivo within their native epiblast
context (not just within ESCs in vitro). This seems to be a likely
contingency because around the time of gastrulation, Oct4,
Sox2, and Nanog are no longer expressed throughout the
entire epiblast, but instead, they are only expressed by select
subpopulations of cells that are already fated to differentiate
into certain germ layers (reviewed by Teo et al., 2011). Such
lineage-restricted expression raises the formal possibility that
individual pluripotency factors may specify epiblast differentia-
tion to particular germ layers. Indeed,Oct4 is upregulated during
mesodermal commitment of the epiblast—and conspicuously, if
Oct4 is knocked down, postimplantation epiblast cells are
largely incapable of mesodermal differentiation (Zeineddine
et al., 2006).
The construction of inducible pluripotency factor-knockout
embryos would allow for rigorous evaluation of our model by
examiningwhether temporally controlled ablation of pluripotency
factors in the postimplantation epiblast precludes differentiation
to specific fetal lineages. We also predict that in vivo overexpres-
sion of pluripotency factors such as Oct4 and Sox2 within the
early postimplantation epiblast would induce all epiblast cells
to adopt a mesodermal fate or a neuroectodermal fate, respec-
tively, overcoming natural developmental assignment of epiblast
cells to diverse germ layer fates.
Mechanisms Underlying Lineage Specification
Intuitively, if pluripotency factors function as lineage specifiers,
they must bind to and activate the expression of genetic loci
encoding differentiation genes. Consistent with this idea,
pluripotency transcription factors are widely known to bind to
differentiation genes within undifferentiated ESCs (reviewed by
Jaenisch and Young, 2008; Young, 2011). Such interactions
have been previously interpreted to be repressive (Jaenisch
and Young, 2008; Young, 2011), pursuant to the prevailing
model that pluripotency factors constitutively inhibit differentia-
tion. However, finding that a pluripotency factor is bound to
the promoter of a differentiation gene through chromatinimmunoprecipitation (chIP) does not ipso facto mean that it is
repressing its target.
Conversely, when chIP-predicted interactions between
pluripotency factors and differentiation genes were interrogated
at a functional level, it was found that some pluripotency factors
actually potentiate the expression of certain of the lineage spec-
ification genes that they bind (Figure 1B). For example, Nanog
provides human ESCs with the ability to differentiate into defini-
tive endoderm by binding to and directly upregulating the
expression of Eomes, one of the master drivers of definitive
endoderm differentiation (Teo et al., 2011). Likewise, Tbx3
endows mouse ESCs with the capability to differentiate into
primitive endoderm by directly binding to the Gata6 promoter
and displacing the PRC2 H3K27 methyltransferase complex,
thus liberating the endodermal specification gene Gata6 from
repressive H3K27 methylation (Lu et al., 2011).
Pluripotency transcription factors can also help to presage
later differentiation events. For example, Foxd3 binds to the
liver-specific albumin enhancer (in mouse ESCs) and keeps it
free of DNA methylation, such that albumin may later be ex-
pressed in hepatic cells after endodermal determination (Xu
et al., 2009). Similarly, Sox2 targets immunoglobulin lambda for
activatory H3K4 dimethylation within ESCs, such that it may later
be expressed in pro-B lymphocytes after hematopoietic deter-
mination (Liber et al., 2010).
Epigenetic potentiation of differentiation genes by pluripo-
tency factors is difficult to rationalize within the framework of
the existing model (Silva and Smith, 2008). However, with our
present model, it may be readily understood a posteriori that
that these pluripotency factors are simply carrying out their
lineage specification activities and are attempting to upregulate
their downstream lineage-specific genes in order to effect differ-
entiation.
Overall, we suggest that the initial differentiation of ESCs does
not require the activation of some dormant dedicated lineage
specifier that then contends with resident pluripotency factors
to transact differentiation, as previously proposed (Silva and
Smith, 2008). Instead, we aver that pluripotency factors are
themselves dominant lineage specifiers that actively upregulate
specific lineage determinants in undifferentiated ESCs to main-
tain a diverse range of lineage commitment options and to
continually provide opportunities for differentiation. ESCs
already express all the transcription factors required to engage
any major fetal lineage differentiation program and have in
hand all the necessary transcription factors needed to initially
differentiate into any primary fetal germ layer.
Hence, when considering the hierarchical differentiation gene
batteries involved in the specification of embryonic lineages
(reviewed by Davidson, 2010), we assert that pluripotency
factors may be regarded as the highest-level upstream drivers
of any fetal differentiation gene battery (Figure 1B).
Extrinsic Signaling Is Required to Maintain Pluripotency
Superficially, our assignment of pluripotency factors as lineage
specifiersmight seem at oddswith the fact that ESCs expressing
these transcription factors can be perennially maintained in an
undifferentiated state. However, this quandary may be readily
resolved when one considers that an inherent property of lineage
specification factors is the ability to suppress commitment toCell Stem Cell 8, April 8, 2011 ª2011 Elsevier Inc. 365
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Greaves, 1998). Diverse lineage specifiers associatedwithmutu-
ally exclusive lineages are expressed concomitantly in ESCs,
and thus, they must cross-inhibit one anothers’ differentiation-
inducing activities (Figure 1A). The end result is temporary
prevention of commitment to any major fetal lineage and reten-
tion of a net undifferentiated state despite the coexpression of
many lineage specifiers. Thus, we propose that undifferentiated
self-renewal is maintained by a carefully balanced equilibrium of
transcription factors wherein the lineage specifying activities of
individual factors are all counteracted by one another.
We speculate that pluripotency is an intrinsically unstable
state of affairs, as differentiation can be readily elicited by the
stochastic upregulation or downregulation of individual pluripo-
tency factors. Upregulation of particular transcription factors
could directly specify lineage commitment (a` la Oct4). Con-
versely, downregulation of any pluripotency factor would release
its lineage-specific blockade on differentiation, enabling lineage
specifiers directing differentiation to these previously repressed
lineages to proceed unopposed. Such predictions appear to be
substantiated by salient findings that subtle fluctuations in Oct4
or Sox2 expression elicit differentiation (Kopp et al., 2008; Niwa
et al., 2000). Thus, we predict that in order for ESCs to remain
undifferentiated, the expression levels of key pluripotency
factors must be carefully controlled to ensure that no single
factor’s lineage specifying activities become dominant.
Extrinsic cytokine signaling provides a mechanism through
which the expression of various pluripotency factors could be
providently controlled (Figure 2A). For example, in mouse
ESCs, LIF signaling directly upregulates expression of transcrip-
tion factors Klf4 and Tbx3 and indirectly upregulates expression
of Sox2 and Nanog (Niwa et al., 2009), TGFb signaling directly
upregulates Oct4 expression (Zeineddine et al., 2006), and
BMP signaling upregulates Id transcription factors that oppose
neuroectodermal differentiation (Ying et al., 2003), thus restrain-
ing neuroectodermal specifiers such as Sox2. Continual
signaling through these pathways could engineer undifferenti-
ated transcriptional states in which opposing pluripotency
factors are expressed at comparable levels. Thus, we conjecture
that undifferentiated ESC self-renewal may only be enduringly
maintained through continual extrinsic signaling.
The Fallibility of Extrinsic Signaling
However, one may deduce that it would be inherently inefficient
and error-prone to continually maintain undifferentiated states
through the perpetual re-upregulation of opposing pluripotency
factors via extrinsic signaling. Individual cells often respond
heterogeneously, asynchronously, or sometimes not at all to
extrinsic signals. Upon receiving an extrinsic signal, many cells
fail to engage the subordinate signal transduction pathway
and express assigned target genes (Fiering et al., 1990; Tay
et al., 2010). If pluripotency factor expression is acutely
contingent upon extrinsic signaling, then heterogeneous trans-
duction of extrinsic signals by ESCs should generate corre-
spondingly heterogeneous expression of pluripotency factors
among individual ESCs (Figure 2B). Indeed, although Klf4 and
Tbx3 are direct transcriptional targets of LIF signaling, they are
not even expressed by all ESCs (Niwa et al., 2009). Through
re-examination of published data sets (Tang et al., 2010), we366 Cell Stem Cell 8, April 8, 2011 ª2011 Elsevier Inc.have found a previously unrecognized 10-fold variation in both
Oct4 and Sox2 expression (Figure 2B) between individual
ESCs. Other pluripotency factors have also been reported to
be heterogeneously expressed in ESC cultures (reviewed by
Graf and Stadtfeld, 2008).
Variable expression of pluripotency factors with lineage
specifying activities seems potentially problematic, especially
in the case of Oct4 and Sox2, given that only 2-fold variations
in their expression levels are sufficient to elicit differentiation
(Kopp et al., 2008; Niwa et al., 2000). Should our model hold
true, we predict that ESCs expressing exceedingly high levels
ofOct4would be strongly biased toward mesodermal specifica-
tion, and that those with upregulated Sox2 would be predis-
posed to neuroectodermal commitment.
Close Encounters of the Differentiated Kind
Consistent with the lineage-specifying activities of pluripotency
factors, significant proportions of ESCs express multifarious
genes associated with commitment to diverse lineages, such
as the mesodermal specifiers Brachyury and Hes1 (Kobayashi
et al., 2009; Suzuki et al., 2006) and the primitive endodermal
determinants Hhex and Rest (Canham et al., 2010; Yamada
et al., 2010). Individual ESCs expressing Brachyury, Hes1, or
Hhex are significantly predisposed to differentiate into meso-
derm or primitive endoderm, respectively (Suzuki et al., 2006;
Kobayashi et al., 2009; Canham et al., 2010). Fluctuating expres-
sion of lineage specifiers in undifferentiated ESCs probably
underlies the spontaneous differentiation of ESCs at appreciable
frequencies even under optimal culture conditions (Smith, 2001;
Smith et al., 1992). What remains to be done is to correlate upre-
gulation of lineage-specifying pluripotency factors (e.g., Oct4) in
single ESCs with consequential upregulation of lineage determi-
nants (e.g., Brachyury).
Moreover, it appears that individual ESCs are continually
moving to and fro between specific lineage options, as they
may flexibly upregulate and then downregulate lineage speci-
fiers such as Brachyury, losing associated differentiation biases
in the process (Suzuki et al., 2006). It will be insightful to discern
themechanisms that underlie the continual flux of ESCs between
unbiased and lineage-inclined states.
We conclude that spontaneous ESC differentiation in steady-
state culture conditions again reiterates the transcriptional inse-
curity of pluripotency and is reflective of an intrinsic inclination of
ESCs toward lineage commitment. Spontaneous differentiation
is also consistent with a model in which imprecise control of
pluripotency factor expression by extrinsic signals generates
cell-to-cell transcriptional and functional heterogeneity within
ESC cultures.
Can Pluripotency Be Maintained without Extrinsic
Intervention?
Is pluripotency an unstable state of exception that may only
be maintained through continual extrinsic signaling (as we
propose), or is it an intrinsically transcriptionally stable ‘‘ground
state’’ that will indefinitely self-maintain in the absence of all
extrinsic signals (Wray et al., 2010)?
From a physiological perspective, it is often argued that
pluripotency must be intrinsically stable in vivo, as presumptive
epiblast cells can be maintained in a pluripotent state for several
Figure 2. The Mechanisms and Consequences of Maintaining Pluripotency via Extrinsic Signaling
(A) Extrinsic signals attempt tomaintain consistent expression levels of pluripotency factors in order tomaintain undifferentiated self-renewal. We depict here how
LIF signaling, TGFb signaling, and BMP signaling directly upregulate select pluripotency factors (Niwa et al., 2009; Ying et al., 2003; Zeineddine et al., 2006) via
their respective pathway-specific terminal transcriptional effectors in mouse ESCs. These pluripotency transcription factors subsequently cross-regulate one
anothers’ expression, promote installation of favored lineage-specification programs, and prohibit adoption of mutually exclusive lineage specification programs.
Transcriptional cross-regulation of pluripotency factors is partially based on chromatin immunoprecipitation (chIP) data and is thus necessarily tentative.
ENDO, MESO, and ECTO represent the endodermal, mesodermal, and ectodermal differentiation gene batteries, respectively. Dashed lines represent
STAT3-independent regulation of Tbx3 by LIF signaling (Niwa et al., 2009) and indirect regulation of Sall4 by STAT3. Hatched orange lines represent inhibition of
neuroectodermal differentiation by Id3 (Ying et al., 2003) and inhibition of endodermal differentiation by Sox2 (Ivanova et al., 2006).
(B) Individual ESCs display heterogeneous expression of the transcription factors Oct4, Sox2, Nanog, Tbx3, Klf4, Rex1, Stella, and Esrrb. The graphs represent
our analysis of published high-throughput single-cell qPCR results on 14 individual ESCs (Tang et al., 2010), initially normalized to actb expression and then later
normalized to one specific ESC (‘‘ES11’’).
(C) Undifferentiated self-renewal under ‘‘2i’’ conditions entails mouse ESC culture with a MAPK inhibitor (MAPKi; PD0325901) and a GSK3 inhibitor (GSK3i;
CHIR99021). Such ‘‘2i’’ culture conditions are believed to preserve undifferentiated ESCs solely by blockade of differentiation signals (Ying et al., 2008). However,
we believe that ‘‘2i’’ culture conditions still entail active self-renewal signals that direct the upregulation of pluripotency factors. Namely, GSK3 inhibition activates
Wnt/b-catenin signaling and autocrine self-renewal signals innately produced by ESCs still persist.
(D) Undifferentiated ESCs have an inherent proclivity to differentiate, as Oct4 and Sox2 continually upregulate Fgf4 expression, which functions as an autocrine
signal to downregulate Nanog and direct either neuroectodermal or mesodermal commitment (Kunath et al., 2007).




Perspectiveweeks during diapause. However, the prolonged pluripotency
exhibited by the epiblast during diapause is strictly dependent
on LIF signaling (Nichols et al., 2001). Thus, the extended main-
tenance of the epiblast’s pluripotency observed during diapause
is the consequence of extrinsic cytokine signaling (similar to
what self-renewing ESCs experience in vitro) and therefore
does not necessarily reflect an innate transcriptional stability of
the pluripotent condition.
More recent assertions that pluripotency is intrinsically stable
are based on the inception of ‘‘2i’’ culture conditions (Ying et al.,
2008). In brief, it was found that mouse ESCs could be kept
perennially undifferentiated in the absence of any exogenous
cytokines if they were treated with two chemical ‘‘signal inhibi-
tors’’—a MAPK inhibitor and an GSK3 inhibitor—the ‘‘2i’’ culture
regimen (Ying et al., 2008). Such ‘‘2i’’ conditions were thought to
demonstrate that when ESCs were made bereft of all extrinsic
signals (achieved by withdrawal of exogenous cytokines such
as LIF and concomitant addition of ‘‘signal inhibitors’’), they
would remain pluripotent; thus, undifferentiated self-renewal
was proposed to be the ESC transcriptional ‘‘ground state’’ in
the absence of all extrinsic instructions (Silva and Smith, 2008;
Wray et al., 2010; Ying et al., 2008).
We would argue that this conclusion is somewhat premature.
‘‘2i’’ culture conditions do not provide an entirely signal-free
environ for ESC self-renewal. The GSK3 inhibitor is not entirely
a ‘‘signal inhibitor,’’ but rather, it directly activates Wnt/b-catenin
signaling (Figure 2C), a dominant ESC self-renewal pathway
(Sato et al., 2004)—and in fact, the GSK3 inhibitor can be func-
tionally replaced by a direct activator of Wnt/b-catenin signaling,
Wnt3a (Ying et al., 2008). Moreover, ESCs autonomously
produce several cytokines, including Activin/TGFb and BMP4,
that support their own undifferentiated self-renewal in autocrine
fashion (Ogawa et al., 2007; Ying et al., 2003). These autocrine
ESC cytokines could still autonomously direct self-renewal
even in the absence of exogenous cytokines in ‘‘2i’’ culture
conditions (Figure 2C). In short, we believe that ‘‘2i’’ culture
conditions maintain undifferentiated self-renewal in the absence
of exogenous cytokines by alternatively transmitting active self-
renewal signals through the Wnt/b-catenin pathway and auto-
crine signaling loops. One may readily assess our hypothesis
by testing whether ‘‘2i’’ conditions can maintain b-catenin/
ESCs.
It will be inherently difficult to ever demonstrate definitively that
ESCs constitutively self-renew in the absence of extrinsic
signals, given the multitudinous signaling pathways that would
need to be silenced to truly monitor pluripotent cell behavior
bereft of all external cues. Our prediction is that suppression of
differentiation signals alone is not sufficient to maintain ESC
self-renewal. Rather, we argue that some form of direct extrinsic
intervention is always required to continually reinforce the
unstable ESC transcription factor regime and prevent its
collapse at the hands of its resident lineage specifiers.
Pluripotency, the Precarious Potential
In sum, we propose that within pluripotent cells there exists
a state of continual conflict between pluripotency transcription
factors that seek to direct ESC differentiation to opposing line-
ages. Austin Smith previously coined the phrase ‘‘the battlefield
of pluripotency’’ (Smith, 2005), and his descriptor elegantly368 Cell Stem Cell 8, April 8, 2011 ª2011 Elsevier Inc.illustrates our present proposal. We suggest that pluripotency
is inherently ephemeral, as even when ESCs are undifferenti-
ated, they continually produce the autocrine differentiation signal
FGF4 in order to destabilize themselves (see Kunath et al., 2007
and Figure 2D), and their intrinsic lineage specifiers are vying for
dominance among one another in order to instruct commitment
to different lineages. We propose that extrinsic signals must be
continually applied in order to sustain undifferentiated self-
renewal and to ensure that no lineage specifying pluripotency
factor becomes dominant.
The instability of pluripotency that we have proposed here is
compatible with the physiological raison d’eˆtre of pluripotency.
In the early embryo, epiblast cells transiently ascend to pluripo-
tency in order to attain the ability to differentiate into all fetal cell
types. Then, their pluripotency is expended shortly thereafter
within several days to generate all the cells that will populate
the fetus. There is no physiological need for pluripotent cells to
continually persist throughout development or adulthood.
Thus, we believe that no molecular provisions have been made
to ensure that pluripotent cells are capable of long-term inde-
pendent self-maintenance.
We conclude by suggesting a fundamental revision to how the
functions of many pluripotency transcription factors are typically
perceived. Given the extraordinary catalog of lineage commit-
ment options available to pluripotent cells, it is unclear why the
present focus on the function of pluripotency transcription
factors is on how they curtail lineage commitment (Jaenisch
and Young, 2008; Silva and Smith, 2008; Young, 2011). A
complementary appreciation for the lineage specifying activities
of pluripotency factors may help provide an understanding of
what underlies the remarkable multilineage differentiation poten-
tial of pluripotent cells.
ACKNOWLEDGMENTS
We thank L.T. Ang, P.P.L. Tam, K.L. Lee, D.J.C. Heng, M.T. Fuller, S.W.S. Lim,
G. Guo, and three anonymous reviewers for critical review of the manuscript
and evaluation of the model disclosed therein. Moreover, we are indebted to
all members of the embryonic stem cell field whosework over the past 30 years
has provided the inspiration for our present proposal. K.M.L. is supported by
the Davidson Institute of Talent Development and B.L. is supported by the
Singapore Agency for Science, Technology, and Research (A*STAR). This
manuscript is dedicated to Dale L. Woodbury for his provision of uncommon
mentorship.
REFERENCES
Canham, M.A., Sharov, A.A., Ko, M.S.H., and Brickman, J.M. (2010). PLoS
Biol. 8, e1000379.
Chng, Z., Teo, A., Pedersen, R.A., and Vallier, L. (2010). Cell StemCell 6, 59–70.
Davidson, E.H. (2010). Nature 468, 911–920.
Enver, T., and Greaves, M. (1998). Cell 94, 9–12.
Fiering, S., Northrop, J.P., Nolan, G.P., Mattila, P.S., Crabtree, G.R., and
Herzenberg, L.A. (1990). Genes Dev. 4, 1823–1834.
Graf, T., and Enver, T. (2009). Nature 462, 587–594.
Graf, T., and Stadtfeld, M. (2008). Cell Stem Cell 3, 480–483.
Ivanova, N., Dobrin, R., Lu, R., Kotenko, I., Levorse, J., DeCoste, C., Schafer,
X., Lun, Y., and Lemischka, I.R. (2006). Nature 442, 533–538.
Jaenisch, R., and Young, R. (2008). Cell 132, 567–582.
Cell Stem Cell
PerspectiveKobayashi, T., Mizuno, H., Imayoshi, I., Furusawa, C., Shirahige, K., and
Kageyama, R. (2009). Genes Dev. 23, 1870–1875.
Kopp, J.L., Ormsbee, B.D., Desler, M., and Rizzino, A. (2008). Stem Cells 26,
903–911.
Kunath, T., Saba-El-Leil, M.K., Almousailleakh, M., Wray, J., Meloche, S., and
Smith, A. (2007). Development 134, 2895–2902.
Lessard, J.A., and Crabtree, G.R. (2010). Annu. Rev. Cell Dev. Biol. 26,
503–532.
Liber, D., Domaschenz, R., Holmqvist, P.-H., Mazzarella, L., Georgiou, A.,
Leleu, M., Fisher, A.G., Labosky, P.A., and Dillon, N. (2010). Cell Stem Cell
7, 114–126.
Lu, R., Yang, A., and Jin, Y. (2011). J. Biol. Chem. 286, 8425–8436.
Nichols, J., Chambers, I., Taga, T., and Smith, A. (2001). Development 128,
2333–2339.
Nishiyama, A., Xin, L., Sharov, A.A., Thomas, M., Mowrer, G., Meyers, E., Piao,
Y., Mehta, S., Yee, S., Nakatake, Y., et al. (2009). Cell Stem Cell 5, 420–433.
Niwa, H., Miyazaki, J., and Smith, A.G. (2000). Nat. Genet. 24, 372–376.
Niwa, H., Ogawa, K., Shimosato, D., and Adachi, K. (2009). Nature 460,
118–122.
Ogawa, K., Saito, A., Matsui, H., Suzuki, H., Ohtsuka, S., Shimosato, D.,
Morishita, Y., Watabe, T., Niwa, H., and Miyazono, K. (2007). J. Cell Sci.
120, 55–65.
Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., and Brivanlou, A.H. (2004).
Nat. Med. 10, 55–63.
Silva, J., and Smith, A. (2008). Cell 132, 532–536.
Smith, A.G. (2001). Annu. Rev. Cell Dev. Biol. 17, 435–462.
Smith, A. (2005). Cell 123, 757–760.Smith, A.G., Nichols, J., Robertson, M., and Rathjen, P.D. (1992). Dev. Biol.
151, 339–351.
Sun, C., Nakatake, Y., Akagi, T., Ura, H., Matsuda, T., Nishiyama, A., Koide, H.,
Ko, M.S.H., Niwa, H., and Yokota, T. (2009). Mol. Cell. Biol. 29, 4574–4583.
Suzuki, A., Raya, A., Kawakami, Y., Morita, M., Matsui, T., Nakashima, K.,
Gage, F.H., Rodrı´guez-Esteban, C., and Izpisu´a Belmonte, J.C. (2006). Nat.
Clin. Pract. Cardiovasc. Med. 3 (Suppl 1 ), S114–S122.
Tang, F., Barbacioru, C., Bao, S., Lee, C., Nordman, E., Wang, X., Lao, K., and
Surani, M.A. (2010). Cell Stem Cell 6, 468–478.
Tay, S., Hughey, J.J., Lee, T.K., Lipniacki, T., Quake, S.R., and Covert, M.W.
(2010). Nature 466, 267–271.
Teo, A.K.K., Arnold, S.J., Trotter, M.W.B., Brown, S., Ang, L.T., Chng, Z.,
Robertson, E.J., Dunn, N.R., and Vallier, L. (2011). Genes Dev. 25, 238–250.
Wray, J., Kalkan, T., and Smith, A.G. (2010). Biochem. Soc. Trans. 38,
1027–1032.
Xu, J., Watts, J.A., Pope, S.D., Gadue, P., Kamps, M., Plath, K., Zaret, K.S.,
and Smale, S.T. (2009). Genes Dev. 23, 2824–2838.
Yamada, Y., Aoki, H., Kunisada, T., andHara, A. (2010). Cell StemCell 6, 10–15.
Ying, Q.L., Nichols, J., Chambers, I., and Smith, A. (2003). Cell 115, 281–292.
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J.,
Cohen, P., and Smith, A. (2008). Nature 453, 519–523.
Young, R.A. (2011). Cell 144, 940–954.
Yu, P., Pan, G., Yu, J., and Thomson, J.A. (2011). Cell Stem Cell 8, 326–334.
Zeineddine, D., Papadimou, E., Chebli, K., Gineste,M., Liu, J., Grey, C., Thurig,
S., Behfar, A., Wallace, V.A., Skerjanc, I.S., et al. (2006). Dev. Cell 11, 535–546.
Zhang, J., Tam, W.-L., Tong, G.Q., Wu, Q., Chan, H.-Y., Soh, B.-S., Lou, Y.,
Yang, J., Ma, Y., Chai, L., et al. (2006). Nat. Cell Biol. 8, 1114–1123.Cell Stem Cell 8, April 8, 2011 ª2011 Elsevier Inc. 369
